VC
ACHV icon

Vivo Capital’s Achieve Life Sciences ACHV Stock Holding History

Vivo Capital’s Portfolio ACHV Stock Details ACHV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18M Buy
+2,751,032
New +$13.1M 1.64% 24

Other funds holding ACHV

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vivo Capital's ACHV Position: Q2 2026 in Review

Vivo Capital opened a new position in Achieve Life Sciences (ACHV) in Q2 2026: 2,751,032 shares worth $18M. The stake represents 1.64% of the portfolio and ranks #24 among its holdings.

111 funds tracked by Wall St. Rank hold ACHV as of Q2 2026.

  • Vivo Capital held 2,751,032 shares of Achieve Life Sciences worth $18M as of Q2 2026.
  • Achieve Life Sciences was a new Vivo Capital position in Q2 2026.
  • Achieve Life Sciences made up 1.64% of Vivo Capital's portfolio in Q2 2026, its #24 holding.
  • 111 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q2 2026.

Based on Vivo Capital's 13F filing for Q2 2026, filed 14 Aug 2026.